Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to learn whether an investigational device called the Activ-L Artificial Disc is safe and effective in the treatment of degenerative disc disease of the lower (lumbar) spine.
| Condition | Intervention | Phase |
|---|---|---|
|
Degenerative Disc Disease |
Device: Activ-L Artificial Disc Device: ProDisc Total Disc Replacement or Charite Atifical Disc |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Clinical Study to Evaluate the Safety and Effectiveness of the Aesculap Activ-L™ Artificial Disc in the Treatment of Degenerative Disc Disease |
- Overall success relative to baseline [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]Measured by absence of treatment failure; absence or serious device related AE; maintenance or improvement of ROM at index level; maintenance or improvement inneurological status; improvement in ODI score.
- Back Pain, measured at rest using a visual analog scale (VAS); improvement of 20 mm or more on a 100 mm VAS scale at 24 months compared to baseline [ Time Frame: 24 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 414 |
| Study Start Date: | January 2007 |
| Estimated Study Completion Date: | July 2017 |
| Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
|
Device: Activ-L Artificial Disc
Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
|
|
Active Comparator: 2
Implantation of either the ProDisc Total Disc Replacement or the Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
|
Device: ProDisc Total Disc Replacement or Charite Atifical Disc
Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
|
Detailed Description:
The objective of this clinical study is to evaluate the safety and effectiveness of the Activ-L Artificial Disc for treatment of single-level degenerative disc disease of the lumbar spine in patients who have been unresponsive to at least six months of prior conservative care. The hypothesis of the study is that the Activ-L Disc is non-inferior to the control (the Charité® Artificial Disc [DePuy Spine] or ProDisc-L® Total Disc Replacement [Synthes Spine]) with respect to the rate of individual subject success at 24 months. Individual subject success is a composite of effectiveness and safety.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 18 - 60, skeletally mature
Symptomatic DDD with objective evidence of lumbar DDD, with any of the following characteristics by MRI scan:
- instability as defined by ≥ 3mm translation or ≥ 5° angulation.
- osteophyte formation of facet joints or vertebral endplates.
- decreased disc height of >2mm as compared to the adjacent level.
- scarring/thickening of the ligamentum flavum, annulus fibrosis, or facet joint capsule.
- herniated nucleus pulposus.
- facet joint degeneration/changes.
- vacuum phenomenon.
Single level symptomatic disease at L4/L5 or L5/S1.
- six months of unsuccessful conservative treatment
- ODI score ≥ 40/100.
- Surgical candidate for an anterior approach to the lumbar spine.
- Back pain at the operative level only, with or without leg pain.
- Back pain VAS score greater than the higher of the two VAS leg pain scores.
- VAS back pain score ≥ 40/100 mm.
- Willing to return for follow-up visits and sign an Informed Consent and HIPAA Authorization.
Exclusion Criteria:
- Previous surgery at any lumbar level, except IDET (Intradiscal Electrothermal Annuloplasty), percutaneous nucleoplasty, or microdiscectomy.
- Chronic radiculopathy, i.e., subject complaint of unremitting pain with a predominance of leg pain symptoms greater than back pain symptoms extending over a period of at least 1 year.
- endplate dimensions smaller than 34.5 mm in medial-lateral and/or 27 mm in the anterior-posterior direction
- Evidence of significant, symptomatic disc degeneration at another lumbar level.
- Preoperative remaining disc height < 3mm
- Myelopathy.
- Previous compression or burst fracture at the affected level.
- Sequestered herniated nucleus pulposus with migration.
- Mid-sagittal stenosis of <8mm (by MRI).
- Degenerative or lytic spondylolisthesis > 3mm.
- Spondylolysis.
- Isthmic spondylolisthesis.
- Lumbar scoliosis (> 11 degrees of sagittal plane deformity).
- Spinal tumor.
- Active systemic infection or infection at the site of surgery.
- Facet ankylosis or severe facet degeneration.
- Continuing steroid use or prior use for more than 2 months.
- History of allergies to any of the device components.
- Pregnancy or planning to become pregnant within the next 2 years.
- Morbid obesity (BMI >35).
- Investigational drug or device use within 30 days.
- Osteoporosis or osteopenia
- Metabolic bone disease.
- Leg pain with migrated sequestrum fragment.
- History of rheumatoid arthritis, lupus, or other autoimmune disorder.
- Ankylosing spondylitis.
- History of HIV/AIDS or hepatitis that precludes surgery.
- History of deep vein thrombosis, symptoms of arterial insufficiency, or thromboembolytic disease.
- Current or recent history of illicit drug or alcohol abuse, or dependence as defined as the continued use of alcohol despite the development of social, legal, or health problems.
- Life expectancy <5 years.
- Chemotherapy within past 5 years or any cancer other than non-melanoma skin cancer treated with curative intent within the past 5 years.
- Prior nephrectomy.
- Abdominal adhesions, endometriosis, inflammatory bowel disease, Crohn's disease, diverticulitis, ulcerative colitis or other abdominal pathology that would preclude abdominal surgical approach.
- Insulin-dependent diabetes.
- Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, ALS (amyotrophic lateral sclerosis), or multiple sclerosis.
- History of Pelvic Inflammatory Disease.
- Peritonitis.
- Currently in active spinal litigation as a result of medical negligence.
- Prisoner.
- Psychiatric or cognitive impairment that would interfere with the subject's ability to comply with the study requirements, e.g., Alzheimer's disease.
Contacts and Locations| United States, California | |
| Scripps Memorial Hospital La Jolla | |
| La Jolla, California, United States, 92037 | |
| Hoag Memorial Hospital Presbyterian | |
| Newport Beach, California, United States, 92658 | |
| Rancho Specialty Hospital | |
| Rancho Cucamonga, California, United States, 91730 | |
| University of California San Francisco | |
| San Francisco, California, United States, 94143 | |
| St. John's Hospital and Health Center | |
| Santa Monica, California, United States, 90404 | |
| United States, Colorado | |
| University of Colorado Health Sciences Center | |
| Aurora, Colorado, United States, 80045 | |
| United States, Connecticut | |
| Yale University School of Medicine/New Haven Hospital | |
| New Haven, Connecticut, United States, 06520 | |
| United States, Florida | |
| Aventura Hospital and Medical Center | |
| Aventura, Florida, United States, 33180 | |
| University Community Hospital | |
| Tampa, Florida, United States, 33613 | |
| United States, Illinois | |
| Rush University Medical Center | |
| Chicago, Illinois, United States, 60612 | |
| Neurosciences Education and Research Foundation | |
| Peoria, Illinois, United States, 61605 | |
| United States, Minnesota | |
| HealthEast St. John's Hospital | |
| Maplewood, Minnesota, United States, 55109 | |
| United States, New York | |
| Hospital for Special Surgery | |
| New York, New York, United States, 10021 | |
| United States, North Carolina | |
| Carolinas Healthcare | |
| Charlotte, North Carolina, United States, 28203 | |
| United States, Ohio | |
| University Hospitals of Cleveland | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Pennsylvania | |
| Hamot Medical Center | |
| Erie, Pennsylvania, United States, 16507 | |
| United States, Utah | |
| University of Utah | |
| Salt Lake City, Utah, United States, 84112 | |
| Principal Investigator: | Rolando Garcia, M.D. | Orthopedic Care Center |
| Principal Investigator: | James J Yue, M.D. | Yale University |
| Principal Investigator: | Dom Coric, M.D. | Carolina Neurosurgery and Spine Associates |
| Principal Investigator: | Steven Dennis, M.D. | Hoag Memorial Hospital Presbyterian |
| Principal Investigator: | Federico P. Girardi, M.D. | Hospital for Special Surgery, New York |
| Principal Investigator: | Mick Perez-Cruet, M.D. | Michigan Head and Spine Institute |
| Principal Investigator: | Harel Deutsch, M.D. | Rush University Medical Center |
| Principal Investigator: | Glenn Buttermann, M.D. | Midwest Spine Institute |
| Principal Investigator: | Dzung Dinh, M.D. | Neuroscience Education and Research Foundation |
| Principal Investigator: | Vikas Patel, M.D. | University of Colorado, Denver |
| Principal Investigator: | Christopher Ames, M.D. | University of California, San Francisco |
| Principal Investigator: | John Regan, M.D. | St. John's Hospital and Health Center |
| Principal Investigator: | Andrew Dailey, M.D. | University of Utah Medical Center |
| Principal Investigator: | Darren Bergey, M.D. | Rancho Specialty Hospital |
| Principal Investigator: | Brian Dalton, M.D. | Hamot Medical Center |
| Principal Investigator: | Scott Leary, M.D. | Scripps Memorial Hospital La Jolla |
| Principal Investigator: | David Hart, M.D. | University Hospitals Cleveland |
| Principal Investigator: | Antonio Castellvi, M.D. | Foundatin for Orthopaedic Research and Education |
More Information
No publications provided by Aesculap Implant Systems
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Aesculap Implant Systems |
| ClinicalTrials.gov Identifier: | NCT00589797 History of Changes |
| Other Study ID Numbers: | ASC-01 |
| Study First Received: | December 26, 2007 |
| Last Updated: | February 23, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Aesculap Implant Systems:
|
Degenerative Disc |
Additional relevant MeSH terms:
|
Spinal Diseases Intervertebral Disk Degeneration Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 21, 2013